Frank Ruffo

This profile gathers the share dealings of Frank Ruffo in Aclaris Therapeutics, Inc., where the filings describe the role as finance chief. We count 5 filings; the first trade dates from 1 June 2021 and the latest from 10 March 2022.

On the market, this insider has only sold: 2 sales, €195k in total. Besides market trades, the filings include 3 option exercises. 2022 to date brings no purchases and 2 sales.

On 14 March 2022 came the latest disclosure, an open-market sale for €180k in Aclaris Therapeutics, Inc. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.